Overview

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Status:
Completed
Trial end date:
2018-03-28
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
OncoMed Pharmaceuticals, Inc.